← Oncology Approval Tracker

FDA DECISION ·

Ayvakit

avapritinib · Blueprint Medicines

FDA approvalNew or expanded indicationAdvanced systemic mastocytosis
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis, mast cell leukemia and systemic mastocytosis with an associated hematologic neoplasm.

LAMPGEN ANALYSIS

Why it matters

The decision extends KIT inhibition to three advanced mast cell neoplasm subtypes.

What research teams should watch

Capture diagnostic subtype, platelet counts and interruptions so the safety analysis reflects the treated population.

PRIMARY RECORDS

Sources